文献速递白血病

吉西他滨联合艾日布林治疗顺铂不耐受转移性尿路上皮癌的II期试验最终报告

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
PubMed 文献 · J Clin Oncol · 2019-08-07

这项II期试验评估吉西他滨联合艾日布林在顺铂不耐受的初治晚期或复发转移性尿路上皮癌患者中的耐受性和疗效。24例可评估患者中,客观缓解率为50%(95%CI 29%至71%),中位总生存期11.9个月,中位无进展生存期5.3个月。常见治疗相关不良事件包括疲乏、中性粒细胞减少和贫血。

要点

  • 顺铂不耐受转移性尿路上皮癌患者中,吉西他滨联合艾日布林客观缓解率达50%。
  • 中位总生存期11.9个月,中位无进展生存期5.3个月。
  • 常见≥任何级别毒性为疲乏83%、中性粒细胞减少79%、贫血63%。

核心结论

  • 吉西他滨联合艾日布林在顺铂不耐受转移性尿路上皮癌患者中显示出较好的缓解率和生存,但需进一步研究。

研究设计与样本

  • 单臂II期试验采用Simon两阶段设计,入组24例顺铂不耐受的初治晚期或复发转移性尿路上皮癌患者。
  • 顺铂不耐受定义为肌酐清除率低于60 mL/min(但≥30 mL/min)、2级神经病变或2级听力损失。
  • 治疗方案为吉西他滨1000 mg/m2后艾日布林1.4 mg/m2,第1天和第8天静脉给药,21天为一周期。

主要发现

  • 24例患者中12例确认为缓解者,客观缓解率为50%(95%CI 29%至71%)。
  • 中位总生存期为11.9个月(95%CI 5.6至20.4个月),中位无进展生存期为5.3个月(95%CI 4.5至6.7个月)。
  • 最常见任何级别治疗相关毒性为疲乏(83%)、中性粒细胞减少(79%)、贫血(63%)、脱发(50%)、AST升高(50%),便秘、恶心和血小板减少各占42%。

关键数值与推荐

  • 主要终点为客观缓解率,采用RECIST 1.1标准,设计区分20%与50%的缓解率。
  • 入组患者中位年龄73岁(范围62至88岁),体能状态0、1、2分分别有11、11和2例。

临床怎么用

  • 对于顺铂不耐受的转移性尿路上皮癌患者,吉西他滨联合艾日布林可作为备选方案,但需注意疲乏和血液学毒性。

局限性

  • 样本量较小(24例),为单臂II期试验,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Cancer Therapy Evaluation Program-sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribulin combination in this population. METHODS: Patients with treatment-naïve advanced or recurrent metastatic urothelial carcinoma of the bladder, ureter, or urethra not amenable to curative surgery and not candidates for cisplatin-based therapy were eligible. Cisplatin ineligibility was defined as creatinine clearance less than 60 mL/min (but ≥ 30 mL/min), grade 2 neuropathy, or grade 2 hearing loss. Treatment was gemcitabine 1,000 mg/m2 intravenously followed by eribulin 1.4 mg/m2, both on days 1 and 8, repeated in 21-day cycles until progression or unacceptable toxicity. A Simon two-stage phase II trial design was used to distinguish between Response Evaluation Criteria in Solid Tumors, version 1.1 objective response rates of 20% versus 50%. RESULTS: Between June 2015 and March 2017, 24 eligible patients with a median age of 73 years (range, 62 to 88 years) underwent therapy. Performance status of 0, 1, or 2 was seen in 11, 11, and two patients, respectively. Sites of disease included: lymph nodes, 16; lungs, nine; liver, seven; bladder, five; bones, two. Median number of cycles received was four (range, one to 16). Of 24 patients, 12 were confirmed responders; the observed objective response rate was 50% (95% CI, 29% to 71%). Median overall survival was 11.9 months (95% CI, 5.6 to 20.4 months), and median progression-free survival was 5.3 months (95% CI, 4.5 to 6.7 months). The most common treatment-related any-grade toxicities were fatigue (83% of patients), neutropenia (79%), anemia (63%), alopecia (50%), elevated AST (50%), and constipation, nausea, and thrombocytopenia (42% each). CONCLUSION: Gemcitabine-eribulin treatment response and survival for cisplatin-ineligible patients compare favorably to other regimens. Additional research is needed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sadeghi S, Groshen SG, Tsao-Wei DD, et al. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019. PMID: 31390274. doi:10.1200/JCO.19.00861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。